Johnson & Johnson (J&J) has officially announced clinical Phase 3 data validating that a combination of its oncology mainstay Darzalex Faspro and immunotherapy Talvey significantly reduced the risk of disease progression or death in individuals presenting with multiple myeloma. The landmark survival outcomes successfully pave the way for a potential regulatory label expansion engineered to advance Talvey into earlier therapeutic lines. The clinical dataset debuted at the European Hematology Association (EHA) annual meeting and was formally published in The New England Journal of Medicine (NEJM).
The documented survival risk reduction parameters, molecular bispecific target designs, and J&J oncology portfolio financial metrics feature:
-
Quantified Clinical Survival and Progression Risk Decelerations:
-
Mortality Risk Reduction Metrics: Long-term evaluation metrics after two years demonstrated that the investigative regimen pairing Talvey and Darzalex Faspro, administered with or without the oncology medication Pomalyst, reduced the absolute risk of death by as much as 53% when benchmarked against the active standard-of-care regimen in relapsed or refractory multiple myeloma cohorts.
-
Progression Free Superiority: Additionally, the combined drug sequence slashed the overall risk of pathological disease progression or death by up to 72%. J&J verified that these Phase 3 results stand as the first to conclusively demonstrate superior progression-free survival (PFS) utilizing a GPRC5D-targeted bispecific antibody combination within an earlier-line multiple myeloma treatment architecture.
-
-
Molecular Mechanisms of Action Characterizing the Talvey Immunotherapy:
-
Portfolio Strategy Realignment: While Darzalex has long maintained its position as an established cornerstone of multiple myeloma care, Talvey operates as a central player in J&J’s aggressive drive to diversify its hematological malignancy offerings. This pipeline expansion is highly critical as the drugmaker navigates plummeting commercial revenues from its blockbuster autoimmune therapy, Stelara, which faces severe market erosion from incoming biosimilar competition.
-
Dual-Binding Target Architecture: Talvey functions as a next-generation bispecific antibody, originally securing its baseline regulatory approval in fiscal year 2023 for heavily pre-treated adults who had failed at least four prior lines of systemic therapy. The molecule triggers targeted immunotherapy by simultaneously binding to the CD3 receptor complex on host immune T-cells while precision-targeting GPRC5D, a specialized protein highly expressed on malignant blood plasma cells.
-
-
Corporate Revenue Growth Trajectories and Global Regulatory Pipelines:
-
Commercial Monetization Volatilities: Despite its status as a younger commercial asset, Talvey generated $463 million in global revenue for fiscal year 2025, charting a robust 61% increase over its first full market year which sat at $287 million.
-
Oncology Segment Acceleration: Supported by this expanding immunotherapy engine, J&J’s consolidated oncology business unit expanded by 22% year-over-year, driving total division sales from $20.8 billion in fiscal year 2024 up to $25.4 billion in 2025. Backed by the positive Phase 3 endpoints, J&J confirmed it is actively working alongside federal health authorities in the United States and Europe to formalize the label expansion bids and fast-track the combination regimen into clinical practice.
-
Source: https://www.biopharmadive.com/news/jj-multiple-myeloma-drug-talvey-earlier-stage-disease/822904/